{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:14:39Z","timestamp":1786119279567,"version":"build-2736575974"},"reference-count":32,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,1]]},"DOI":"10.1097\/ico.0b013e3181ae91e3","type":"journal-article","created":{"date-parts":[[2009,12,21]],"date-time":"2009-12-21T10:42:38Z","timestamp":1261392158000},"page":"86-92","source":"Crossref","is-referenced-by-count":22,"title":["The Effect of Subconjunctival Suramin on Corneal Neovascularization in Rabbits"],"prefix":"10.1097","volume":"29","author":[{"given":"Hyun Soo","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung Kun","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-15-20210204","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/S1074-5521(96)90176-3","article-title":"Integrins, angiogenesis and vascular cell survival.","volume":"3","author":"Stromblad","year":"1996","journal-title":"Chem Biol"},{"key":"R2-15-20210204","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1097\/00055735-200108000-00002","article-title":"Corneal neovascularization.","volume":"12","author":"Chang","year":"2001","journal-title":"Curr Opin Ophthalmol"},{"key":"R3-15-20210204","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S0074-7696(08)62106-3","article-title":"Angiogenesis: models and modulators.","volume":"159","author":"Cockerill","year":"1995","journal-title":"Int Rev Cytol"},{"key":"R4-15-20210204","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.vph.2006.01.005","article-title":"Angiogenesis: a new target for future therapy.","volume":"44","author":"Pandya","year":"2006","journal-title":"Vascul Pharmacol"},{"key":"R5-15-20210204","first-page":"S832","article-title":"Characterization of angiostatin in the mouse cornea.","volume":"41","author":"Chang","year":"2000","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R6-15-20210204","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.yexcr.2005.11.015","article-title":"Antiangiogenesis in cancer therapy: endostatin and its mechanisms of action.","volume":"312","author":"Folkman","year":"2006","journal-title":"Exp Cell Res"},{"key":"R7-15-20210204","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1111\/j.1600-0420.2007.01049.x","article-title":"Safety, penetration and efficacy of topically applied bevacizumab: evaluation of eyedrops in corneal neovascularization after chemical burn.","volume":"86","author":"Yoeruek","year":"2008","journal-title":"Acta Ophthalmol"},{"key":"R8-15-20210204","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s002800050885","article-title":"Inhibitory effect of suramin in rat models of angiogenesis in vitro and in vivo.","volume":"43","author":"Bocci","year":"1999","journal-title":"Cancer Chemother Pharmacol"},{"key":"R9-15-20210204","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa032691","article-title":"Bevacizumab plusirinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.","volume":"350","author":"Hurwitz","year":"2004","journal-title":"N Engl J Med"},{"key":"R10-15-20210204","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.ophtha.2005.11.019","article-title":"Intravitreal bevacizumab(Avastin) for neovascular age-related macular degeneration.","volume":"113","author":"Avery","year":"2006","journal-title":"Ophthalmology"},{"key":"R11-15-20210204","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1097\/00006982-200603000-00004","article-title":"Intravitreal Bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage.","volume":"26","author":"Spaide","year":"2006","journal-title":"Retina"},{"key":"R12-15-20210204","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.ajo.2007.11.003","article-title":"Inhibition of corneal neovascularization by subconjunctival bevacizumab in an animal model.","volume":"145","author":"Papathanassiou","year":"2008","journal-title":"Am J Ophthalmol"},{"key":"R13-15-20210204","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/j.ophtha.2007.01.017","article-title":"Pharmacokinetics of intravitreal bevacizumab (Avastin).","volume":"114","author":"Bakri","year":"2007","journal-title":"Ophthalmology"},{"key":"R14-15-20210204","first-page":"289","article-title":"Suramin with special reference to onchocerciasis.","volume":"15","author":"Hawking","year":"1989","journal-title":"Adv Pharmocol Chemother"},{"key":"R15-15-20210204","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1006\/jsre.2000.5920","article-title":"Suramin analogs inhibit human angiogenesis in vitro.","volume":"91","author":"Meyers","year":"2000","journal-title":"J Surg Res"},{"key":"R16-15-20210204","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1002\/ijc.10930","article-title":"Inhibition of heparanase activity and heparanase-induced angiogenesis by suramin analogues.","volume":"104","author":"Marchetti","year":"2003","journal-title":"Int J Cancer"},{"key":"R17-15-20210204","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s002800050717","article-title":"Antiangiogenic and antiproliferative activity of suramin analogues.","volume":"41","author":"Gagliardi","year":"1998","journal-title":"Cancer Chemother Pharmacol"},{"key":"R18-15-20210204","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1006\/jmcc.1996.0142","article-title":"Suramin is a potent inhibitor of vascular endothelial growth factor. A contribution to the molecular basis of its antiangiogenic action.","volume":"28","author":"Waltenberger","year":"1996","journal-title":"J Mol Cell Cardiol"},{"key":"R19-15-20210204","first-page":"94","article-title":"Inhibition of ocular neovascularization by suramin.","volume":"35","author":"Joussen","year":"1995","journal-title":"Vision Res"},{"key":"R20-15-20210204","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1038\/sj.bjc.6602650","article-title":"Phase I trial of intravesical Suramin in recurrent superficial transitional cell bladder carcinoma.","volume":"92","author":"Ord","year":"2005","journal-title":"Br J Cancer"},{"key":"R21-15-20210204","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1002\/lsm.1900170207","article-title":"In vivo uptake of liposomal benzoporphyrin derivative and photothrombosis in experimental corneal neovascularization.","volume":"17","author":"Schmidt-Erfurth","year":"1995","journal-title":"Lasers Surg Med"},{"key":"R22-15-20210204","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1097\/00003226-200110000-00013","article-title":"Expression of vascular endothelial growth factor and inducible nitric oxide synthase in pterygia.","volume":"20","author":"Lee","year":"2001","journal-title":"Cornea"},{"key":"R23-15-20210204","first-page":"2514","article-title":"Expression of vascular endothelial growth factor and its receptors in inflamed and vascularized human corneas.","volume":"41","author":"Philipp","year":"2000","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R24-15-20210204","first-page":"264","article-title":"Corneal angiogenic privilege: angiogenic and antiangiogenic factors in corneal avascularity, vasculogenesis, and wound healing (an American Ophthalmological Society thesis).","volume":"104","author":"Azar","year":"2006","journal-title":"Trans Am Ophthalmol Soc"},{"key":"R25-15-20210204","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.preteyeres.2008.05.001","article-title":"Vascular endothelial growth factor in eye disease.","volume":"27","author":"Penn","year":"2008","journal-title":"Prog Retin Eye Res"},{"key":"R26-15-20210204","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0006-2952(00)00529-3","article-title":"Angiogenesis: regulators and clinical applications.","volume":"61","author":"Liekens","year":"2001","journal-title":"Biochem Pharmacol"},{"key":"R27-15-20210204","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S0065-230X(08)00004-3","article-title":"Molecular mechanisms and therapeutic development of angiogenesis inhibitors.","volume":"100","author":"Cao","year":"2008","journal-title":"Adv Cancer Res"},{"key":"R28-15-20210204","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1167\/iovs.06-0570","article-title":"Bevacizumab as a potent inhibitor of inflammatory corneal angiogenesis and lymphangiogenesis.","volume":"48","author":"Bock","year":"2007","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R29-15-20210204","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1136\/bjo.82.7.816","article-title":"Suramin inhibits wound healing following filtering procedures for glaucoma.","volume":"82","author":"Mietz","year":"1998","journal-title":"Br J Ophthalmol"},{"key":"R30-15-20210204","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1097\/ICO.0b013e3180de1d0a","article-title":"Safety profile of bevacizumab on cultured human corneal cells.","volume":"26","author":"Yoeruek","year":"2007","journal-title":"Cornea"},{"key":"R31-15-20210204","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1023\/A:1015666024386","article-title":"Suramins development: what did we learn?","volume":"20","author":"Kaur","year":"2002","journal-title":"Invest New Drugs"},{"key":"R32-15-20210204","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1097\/ICO.0b013e31815cf67d","article-title":"Inhibition of experimental corneal neovascularization by using subconjunctival injection of bevacizumab (Avastin).","volume":"27","author":"Kim","year":"2008","journal-title":"Cornea"}],"container-title":["Cornea"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00003226-201001000-00015","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:10:16Z","timestamp":1786039816000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00003226-201001000-00015"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,1]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010]]}},"URL":"https:\/\/doi.org\/10.1097\/ico.0b013e3181ae91e3","relation":{},"ISSN":["0277-3740"],"issn-type":[{"value":"0277-3740","type":"print"}],"subject":[],"published":{"date-parts":[[2010,1]]}}}